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Abstract
Purpose—Peri-implantitis is one of the most common inflammatory complications in dental
implantology. Similar to periodontitis, in peri-implantitis, destructive inflammatory changes take
place in the tissues surrounding a dental implant. Bacterial flora at the failing implant sites
resemble the pathogens in periodontal disease and consist of Gram-negative anaerobic bacteria
including Aggregatibacter actinomycetemcomitans (Aa). Here we demonstrate the effectiveness of
a silver lactate (SL)-containing RGD-coupled alginate hydrogel scaffold as a promising stem cell
delivery vehicle with antimicrobial properties.
Materials and Methods—Gingival mesenchymal stem cells (GMSCs) or human bone marrow
mesenchymal stem cells (hBMMSCs) were encapsulated in SL-loaded alginate hydrogel
microspheres. Stem cell viability, proliferation, and osteo-differentiation capacity were analyzed.
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Results—Our results showed that SL exhibited antimicrobial properties against Aa in a dosedependent manner, with 0.50 mg/ml showing the greatest antimicrobial properties while still
maintaining cell viability. At this concentration, SL-containing alginate hydrogel was able to
inhibit Aa on the surface of Ti discs and significantly reduce the bacterial load in Aa suspensions.
Silver ions were effectively released from the SL-loaded alginate microspheres for up to 2 weeks.
Osteogenic differentiation of GMSCs and hBMMSCs encapsulated in the SL-loaded alginate
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microspheres were confirmed by the intense mineral matrix deposition and high expression of
osteogenesis-related genes.
Conclusion—Taken together, our findings confirm that GMSCs encapsulated in RGD-modified
alginate hydrogel containing SL show promise for bone tissue engineering with antimicrobial
properties against Aa bacteria in vitro.
Keywords
Alginate hydrogel; antimicrobial properties; silver; mesenchymal stem cell; bone regeneration
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Peri-implantitis is characterized by an inflammatory reaction in the tissues surrounding
dental implants, with clinical features such as soft tissue inflammation (bleeding upon
probing and suppuration) and progressive loss of supporting bone beyond biological bone
remodeling.1,2 Peri-implant bone loss is one of the most common inflammatory
complications in craniofacial implantology.1 Like periodontitis, peri-implantitis occurs
mainly as a result of an overwhelming bacterial insult and subsequent host immune
response.1–3 It has been shown that bacterial species associated with periodontitis and
periimplantitis are similar, including mainly Gram-negative anaerobes such as
Porphyromonas gingivalis, Prevotella intermedia, and Aggregatibacter
actinomycetemcomitans (Aa).1–3 In particular, Aa, a facultative Gram-negative bacterium,
appears to play an important role in certain types of periodontal disease.4 Aa, or organisms
likely to be Aa, have been isolated in high numbers from young patients with rapidly
progressing alveolar bone breakdown.4 It has been shown that Aa can form a biofilm on
titanium implants, which can in turn be used as a colonizing surface, allowing in vivo
bacterial persistence and inflammatory host response.11 In addition, inflammatory cells, with
B-lymphocytes and plasma cells being the most dominant among them, infiltrate the
connective tissue adjacent to the pocket epithelium. Pro-inflammatory cytokines (e.g., IL-1,
IL-6, IL-8, and TNF-α) are up-regulated in peri-implantitis.6–8 Studies have confirmed that
biofilm formation plays an important role in the initiation and progression of peri-implant
disease and is critical for the development of infection around dental implants. Biofilm
organisms differ significantly from their planktonic counterparts, as they are characterized
by cells that have developed into a community rather than simply being attached to a
surface.9 These organisms are embedded in an extracellular polymer produced by bacterial
cells. Furthermore, biofilm organisms exhibit an altered phenotype with respect to growth
rate, gene transcription, and antimicrobial resistance.10–12 Therefore, to introduce a
predictable treatment modality for peri-implant bone loss, it is necessary to focus on
managing the biofilm and biofilm organisms. Studies have shown that nonsurgical therapies
might not be as effective as surgical treatment modalities.
Mesenchymal stem cells (MSCs) present an advantageous therapeutic option for bone tissue
engineering in applications like this one. Recent studies have confirmed that MSCs derived
from craniofacial structures such as gingival mesenchymal stem cells (GMSCs) have
comparable differentiation capacities to bone marrow mesenchymal stem cells
(BMMSCs).13 Additionally, GMSCs are of particular interest as they can be harvested
easily, are accessible through the oral cavity and can be obtained as discarded biological
samples in dental clinics. Furthermore, MSCs possess profound immunomodulatory
J Prosthodont. Author manuscript; available in PMC 2016 February 26.
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properties and can inhibit the proliferation and function of several major types of immune
cells (e.g., dendritic cells, T and B lymphocytes, and natural killer [NK] cells).14,15 In
addition, MSCs are known to have very low immunogenic properties due to low MHC class
I expression levels and being negative for MHC class II.16,17 It has been reported that MSCmediated bone regeneration is partially controlled by the host local microenvironment,
including the presence of growth factors as well as host immune cells and cytokines.18
Scaffolds seeded with appropriate MSCs can create a suitable microenvironment for bone
regeneration therapies, providing nutrients essential for prolonged cell viability, along with
factors that promote osteogenic potential.19–22 In our previous studies, we have shown that
alginate hydrogel is a promising scaffold for the encapsulation of dental MSCs.23,24
Alginates are natural heteropolysaccharides isolated from brown sea algae25,26 with a wide
variety of biomedical applications, including the encapsulation of cells and sensitive
bioactive molecules, and are both injectable and biodegradable.27,28 Recently, we have
developed a novel 3D scaffold based on RGD-coupled alginate hydrogel for the
encapsulation of GMSCs for bone regeneration.23,24,29 However, alginate scaffolds
containing antibacterial agents have never been used as a delivery vehicle for MSCmediated bone regeneration as a treatment for biofilm-mediated peri-implant bone loss.
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Silver (Ag) is one of the most widely used bactericidal agents available.30 Ag is considered
to have a broad antimicrobial spectrum and is less prone to microbial resistance than
antibiotics, especially if rapid bactericidal action is achieved.31,32 Although silver is
relatively inert, its interaction with moisture leads to the release of silver ions, which are
highly cytotoxic to microorganisms.16 To achieve its biocidal effect, the required Ag dose is
typically low enough to spare mammalian cell functions.33 Many research groups have
already explored the association of silver and biomaterials or have attached Ag to the
implant itself as a means of preventing bacterial colonization, especially in the initial period
after implant placement.34–39
A literature search failed to reveal any reports evaluating the application of GMSCs
encapsulated in RGD-coupled alginate microspheres containing antimicrobial agents in bone
regenerative therapy for peri-implantitis. Therefore, in the current study, we developed an
injectable and 3D RGD-coupled alginate hydrogel cell encapsulation system containing
silver lactate (SL). Considering the fact that GMSCs can be obtained as discarded biological
samples from dental clinics and are easily harvested from the oral cavity, they can be
considered ideal for stem cell banking purposes provided they show promise in MSC-based
tissue regeneration. This approach was designed to optimize antimicrobial activity against a
common periodontal pathogen (Aa) and to promote bone formation.
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Materials and methods
Progenitor cell isolation and culture
Human GMSCs were isolated and cultured according to previously published procedures.40
Teeth and gingival tissue were obtained from 20 healthy patients (18–25 years old)
undergoing third molar extractions with IRB approval from the University of Southern
California. Subjects with history of periodontal disease were excluded from this study.
Human BMMSCs were processed from marrow aspirates of normal human adult volunteers
J Prosthodont. Author manuscript; available in PMC 2016 February 26.
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(20–35 years of age). MSCs were cultured in α-MEM (Invitrogen, Grand Island, NY)
supplemented with 15% fetal bovine serum (FBS, Invitrogen), 180mMascorbic acid (SigmaAldrich, St. Louis, MO), 100 units/ml penicillin (Invitrogen), and 100 µg/ml streptomycin
(Invitrogen). Passage four cells were used in all experiments.
Biomaterial fabrication, SL incorporation, and cell encapsulation
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Custom-made RGD-coupled alginate with high guluronic acid content (NovaMatrix FMC
Biopolymer, Sandvika, Norway) was used in this study. A 1% (w/v) sodium alginate
solution was made with deionized water and sodium alginate according to our previous
publications.40–42 A stock solution of 5 mg/ml SL (Sigma-Aldrich) and alginate was
prepared by agitation in a mixer overnight at room temperature. Five other concentrations
(0.1, 0.25, 0.5, and 0.75 mg/ml SL) were prepared by serial dilution of the stock solution.
The mixtures were agitated overnight at room temperature. Next, SL-loaded alginate
microspheres were created by adding the solution dropwise to a 100 mM calcium chloride
(CaCl2) solution at 37°C. The microspheres were left to crosslink in the CaCl2 solution for 7
minutes and subsequently rinsed with 0.9% NaCl solution.
GMSCs and hBMMSCs (as a positive control) were encapsulated separately in alginate
loaded with SL. Cells were encapsulated at a density of 1×106 cells/ml of alginate solution.
Microsphere formation was accomplished by adding the MSC-alginate mixture dropwise to
100 mM CaCl2 solution. The resulting microspheres were incubated at 37°C for 45 minutes
to complete cross-linking and then washed three times in nonsupplemented DMEM.
Cytotoxicity
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The cytotoxicity of each SL-loaded alginate formulation was evaluated using a 3-(4,5dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (Invitrogen) assay. GMSCs
and hBMMSCs were plated at a cell density of 5 × 104 cells/ml in 96-well plates. After 24
hours, one microsphere of each SL-loaded alginate formulation was added to each well.
Four replicate plates were made in total. After 24 hours and 7 days of culturing in regular
media, microspheres were removed, and then 10 µl of the MTT solution was added to the
cell monolayers. Next, 90 µl of α-MEM without supplementation was added to the wells.
Plates were then incubated for 4 hours at 37°C in the dark. Formazan crystals formed during
this process were extracted by adding 50 µl of dimethyl sulfoxide (DMSO). After 15
minutes, the absorbance was measured at 570 nm using a microplate reader.
SL activity against aggregatibacter actinomycetemcomitans (Aa)

Author Manuscript

Titanium disc surface treatment—The surfaces of machined 1.0 × 1.0 × 0.1 cm3
titanium (Ti) slabs were modified by grit blasting with silicon carbide (180 and 600) to
produce rough surfaces before Aa inoculation.
Bacteria culture conditions—A purchased A. actinomycetemcomitans strain (ATCC®
33384™, Manassas, VA) was recovered from a lyophilized pellet and grown overnight in 5
ml of brain heart infusion broth (BHI; BD Biosciences, San Jose, CA) in an incubator (37°C,
5% CO2, 220 rpm). The antimicrobial activity of the alginate microspheres containing
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different concentrations of SL against the Aa was determined by qualitative (Parallel Streak
Method) and quantitative evaluation (AATCC100).
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Qualitative analysis of the inhibition zone—Microspheres containing 0, 0.5, and 2.5
mg/ml SL were placed on a lawn of bacteria on Ti discs on a BHI agar plate and incubated
overnight at 37°C. Each lawn was prepared by spreading a 0.5 McFarland (optical density at
600 nm [OD600] of approximately 0.08–0.1) suspension of bacteria in broth using a sterile
swab. Bactericidal activity was visually assessed to determine the zone of inhibition around
each microsphere 24 hours and 5 days after contact of the microspheres with the inoculated
bacterium. At least four replicates were performed for each experimental group. Four
samples were randomly selected from each group, and then the diameter of the zone of
inhibition, subtracted from the microsphere diameter, was calculated for each group and
shown as distance in pixels using NIH Image J software (Version 1.64, NIH, Bethesda,
MD).
Quantitative antimicrobial analysis of SL containing alginate microspheres—
A direct quantitative evaluation of the antimicrobial activity of the SL incorporated in the
alginate microspheres was also performed. Microspheres containing 0, 0.5, and 2.5 mg/ml
SL (n = 10 microspheres per group) were soaked in 2 ml BHI broth inoculated with Aa at an
initial concentration OD600 of 0.3. To control the accuracy of bacterial density, bacteria
were serially diluted in PBS to 103, 104, 105, and 106 colony forming units (CFU/ml) and
plated overnight (200 µl/plate). Suspensions were then incubated at 37°C for 24, 72, and 120
hours.
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Release profile of SL—Sodium alginate microspheres containing two different
concentrations of SL (n = 10 microspheres per group), 0.5 mg/ml (as best working
concentration for eukaryotic cells), and 2.5 mg/ml, measuring approximately 20 µl each,
were soaked in 1 ml double distilled water (ddH2O) and maintained in an incubator at 37°C
and 5% CO2 for 24 hours and 7 and 14 days. Neutron activation analysis (NAA) (Elemental
Analysis, Inc., Lexington, KY) was used to measure and quantify the concentration of silver
ions released in ddH2O at each time point. NAA is a technique based on nuclear reactions
whereby the element of interest is determined by irradiating the sample with neutrons,
creating radioactive forms of the desired element, in this case Ag, in the sample. Counting is
done using the relative amounts of detected gamma rays, which are proportional to the
concentrations of the elements in the sample.43
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In vitro osteogenic induction assay—Encapsulated GMSCs or hBMMSCs in alginate
hydrogels (with or without SL) were cultured in osteogenic media containing 2 mM bglycerophosphate (Sigma-Aldrich), 100 mM l-ascorbic acid 2-phosphate, and 10 nM
dexamethasone (Sigma-Aldrich). Alginate microspheres without cells were used as a
negative control (−). After 4 weeks of osteogenic induction, the osteogenic differentiation
potential of encapsulated MSCs were analyzed using Alizarin red S (ARS) dye, which
distinguishes the presence of calcified deposits. Briefly, the alginate hydrogel microspheres
were fixed in 4% (v/v) paraformaldehyde for 30minutes prior to the serial dehydration
process according to the methods already in the literature.41,42 Next, 6-µm-thick paraffin
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embedded sections were prepared. They were then stained with 2% (w/v) ARS dye solution
for 5 minutes, and excess dye was removed by washing twice with deionizedwater. Images
were captured using an Olympus DP50 digital camera (Olympus Optical Co., Miami, FL),
and retained ARS was analyzed and quantified using NIH ImageJ software by determining
the area positive for dye staining expressed as a fraction of the total area.
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RNA isolation, reverse transcription and real-time PCR—GMSCs and hBMMSCs
were encapsulated in SL-loaded alginate hydrogels, and after 2 weeks of osteogenic
differentiation, 10 alginate hydrogel microcapsules were collected and dissolved in an sterile
depolymerization buffer consisting of 50 mM sodium citrate dehydrate and 80 mM sodium
chloride (Sigma Aldrich) for 20 minutes. Following dissolution, the de-capsulated cells were
centrifuged at 10,000 × g for 10 minutes, and the pellet was washed with PBS and
centrifuged again at 10,000 × g for 3 minutes. Total RNA was extracted using Trizol reagent
(Invitrogen) according to the manufacturer’s recommendations. Single-stranded cDNA
synthesis was performed with 100 ng total RNA using a Superscript III cDNA synthesis kit
(Invitrogen). Data were analyzed using the 2−ΔΔCt method, with normalization to the Ct of
the housekeeping gene GAPDH. Primer and probe sequences are described in Table 1.
SEM analysis
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To characterize the morphology of the alginate scaffolds and encapsulated cells, scanning
electron microscopy (SEM) (JEOL 5300, Peabody, MA) was used. In addition, the lawn of
bacteria on the Ti disc surfaces after 5 days in contact with the alginate microspheres
containing 0.5 mg/ml SL was also visualized by SEM. Briefly, samples were fixed with
glutaraldehyde 2.5% in PBS, washed twice in 0.1 M cacodylate buffer, and post-fixed with
2% osmium tetroxide in 0.1 M cacodylate buffer. Then, samples were dehydrated in graded
alcohol (50%, 70%, 85%, 95%, and 100%) and alcohol/HDMS (v/v) (50/50, 75/25, 85/15,
and 95/5). Next, samples were left to dry overnight, mounted in metal stubs and sputter
coated with gold (25 mA, 10−1 vacuum, 2 minutes).
Statistical analysis
Quantitative data were expressed as mean and standard deviation (SD). One-way and twoway ANOVA, followed by Tukey test at a significance level of a=0.05, were used for
comparison among multiple sample means.

Results
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In this in vitro study, we developed a 3D MSC delivery vehicle based on alginate and tuned
for the local delivery of SL with a defined and predictable drug release profile (Fig 1). After
24 hours or 7 days, cell monolayers in contact with the SL-loaded alginate microspheres
were evaluated using MTT assays. Both GMSCs and hBMMSCs exhibited dose-dependent
cytotoxicity when in contact with SL at a concentration of 0.1 to 0.75 mg/ml (Fig 2).
Regardless of the cell type and time interval assessed, cell viability started to decrease when
SL was used at concentrations above 0.5 mg/ml. After 24 hours, SL-loaded alginate at 0.75
mg/ml significantly reduced cell viability in comparison to all other concentrations,
irrespective of the cell type (p < 0.05) (Fig 2A). After 7 days in culture, SL-loaded alginate
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at 0.75 mg/ml had significantly lower cell viability than the control group, for GMSC and
hBMMSC cultures (p < 0.05) (Fig 2B).
The release profiles of silver ions from the alginate incorporated with two SL concentrations
were evaluated after 24 hours and 7 and 14 days by NAA. The results showed sustained
release of silver ions for up to 14 days (Fig 3).
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According to the obtained SL cytotoxicity data, 0.5 mg/ml was selected as the optimal
concentration for the investigation of antimicrobial activity of the SL-loaded alginate against
Aa bacteria. An SL concentration 5× greater (2.5 mg/ml) was used for comparison. Alginate
alone was used as a negative control. After 1 and 5 days, qualitative analysis of the
antimicrobial properties of the SL-loaded alginate against a biofilm layer of Aa seeded on
the surface ofTi discs indicated zones of inhibition (ZI) around all scaffolds with SL
incorporation (Parallel Streak Method) (Fig 4). No ZI was observed against bacteria in the
group in which alginate was used without the SL (Fig 4A).SEM analysis of the Ti discs with
Aa biofilm in contact with a 0.5 mg/ml SL-loaded alginate microsphere confirmed the
presence of a ZI produced by the antimicrobial agent (Fig 5).
Quantitatively, there was no significant difference in the ZI size in the 0.5 mg/ml and 2.5
mg/ml SL groups after 24 hours of contact with the Aa (Fig 6A). After 5 days, the ZI of both
SL concentrations were significantly smaller than at 24 hours (p < 0.05). Moreover, the ZI
of the 0.5 mg/ml group after 5 days was larger than that of the 2.5 mg/ml group (p = 0.035);
meanwhile, there was significant microsphere shrinkage in the 2.5 mg/ml group (p = 0.044).
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The antimicrobial activity of SL was also tested in Aa suspensions (Fig 6B). After 24 and 72
hours, all SL-loaded alginate concentrations were able to significantly (P < 0.05) reduce the
Aa bacterial load. After 120 hours (5 days), the antimicrobial activity against Aa suspensions
was no longer observed for SL-loaded alginate with concentrations less than 0.5 mg/ml.
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Next, GMSCs and hBMMSCs were encapsulated in the 0.5-mg/ml SL-loaded alginate and
osteo-differentiation of encapsulated MSCs was analyzed in the presence of the
antimicrobial agent. The expression levels of the osteogenic genes RUNX2 and PCN were
confirmed and compared via RT-PCR. Our results revealed that GMSCs as well as
hBMMSCs expressed RUNX2 and OCN abundantly after 2 weeks under osteogenic
induction in the presence of in 0.5 mg/ml SL (Fig 7). The osteogenic differentiation of
encapsulated GMSCs or hBMMSCs in SL-containing alginate hydrogels were analyzed
using Alizarin red S (ARS) staining. After 4 weeks, both GMSC and hBMMSC groups
differentiated into nodules that stained positively with ARS, indicative of their osteogenic
fate (Fig 8A), while the negative control group (alginate alone with no induction) failed to
exhibit any positive staining. The quantification of the mineral matrix deposition using
Image J confirmed that both GMSCs and hBMMSCs produced significantly more mineral
nodules than the negative control (Fig 8B). The results confirmed the possibility of osteodifferentiation of encapsulated GMSCs in the presence of SL at an optimized concentration.
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Discussion
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Peri-implant bone loss remains a serious surgical complication that is difficult to treat.
Accordingly, the avoidance of biofilm buildup on implants is well recognized as being
necessary to guarantee the success of dental implants, preventing their loss and the need for
secondary surgeries; however, besides combating the bacterial buildup, for a successful
surgical outcome it is also necessary to promote tissue integration and repair. Here we
incorporated SL in sodium alginate scaffolds to prevent bacterial contamination and
accelerate bone formation, especially in the initial period after implant placement. We
observed that SL-loaded alginate at 0.5 mg/ml was effective in preventing A.
actinomycetemcomitans (Aa) growth in biofilms and in suspensions. Furthermore, GMSCs
and hBMMSCs encapsulated in the biomaterial showed excellent osteoconductivity, once
MSCs were able to differentiate into osteoblast-like cells and deposit a remarkable amount
of mineral matrix.
We first investigated the cytotoxicity of a range of SL concentrations incorporated in
alginate microspheres and assessed their effects on the viability of GMSCs and hBMMSCs
cell cultures to select a biocompatible SL concentration. SL had a dose-dependent effect on
the viability of both types of MSCs. Regardless of the cell type and time interval assessed,
cell viability started to decrease when SL was used at concentrations at or above 0.5 mg/ml.
SL at 0.5 mg/ml was slightly cytotoxic and was selected to further investigate the SL
antimicrobial activity on Aa bacteria. Our results are in line with other findings in which
biomaterials containing proper concentrations of Ag were shown to be compatible with
eukaryotic cells, such as fibroblasts and osteoblasts.44–47
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We used a commercial Aa strain to further confirm the bacterial activity of SL-containing
alginate hydrogels. When in contact with a lawn of Aa bacteria seeded on Ti discs, alginate
loaded with SL at a concentration of 0.5 mg/ml or 2.5 mg/ml presented clear zones of
inhibition (ZI) around all scaffolds. SEM analysis depicted morphological changes in
bacteria cells immediately in contact with the biomaterial and a large accumulation of
bacteria in the ZI. After 24 and 72 hours of contact, planktonic cultures of Aa were sensitive
to both SL-loaded alginate concentrations, significantly reducing the bacterial load in the
suspensions. At 120 hours, the antimicrobial efficacy diminished. It should be noted that the
bacterial load (>108 CFU/ml) tested here was much larger than what is commonly observed
in contaminated implants in vivo (around 103 CFU/ml).48 Moreover, the antimicrobial
activity of SL-loaded alginate was tested in 2 ml of broth, instead of PBS—a situation where
bacterial growth was being stimulated. Considering its performance in these highly adverse
conditions, SL-loaded alginate may be able to inhibit bacterial growth for longer periods in
vivo.
Paul et al49 tested the antimicrobial activity of silver-particle-incorporated polyurethane
films (1% or 10% [w/w] AgNO3 and 1% or 10% [w/w] SL) against Escherichia coli and
Staphylococcus aureus. They reported that SL performed better than silver nitrate in
inhibiting bacterial growth, even at a low concentration of 1% (w/w) SL. This concentration
is close to the one investigated in our study (0.5 mg/ml or 5% [w/w]). S. aureus (Gram
positive) was less sensitive to the silver antimicrobials than E. coli (Gram negative). Other
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reports corroborate these findings, reporting that the lipopolysaccharide walls of Gramnegative bacteria likely provide an electrostatically attractive surface for silver ions.49 Silver
has antimicrobial activity against a broad range of periodontal pathogens, which are
predominantly Gram-negative, such as the Aa tested here.
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As has been previously reported, the antimicrobial activity of silver is dependent on the
silver cations, which bind strongly to electron donor groups in biological molecules
containing sulfur, oxygen, or nitrogen.39 The highly reactive ionized silver binds to tissue
proteins and produces structural changes in the bacterial cell wall and nuclear membrane,
leading to cell distortion and death.15 Moreover, the binding of silver to bacterial DNA and
RNA inhibits bacterial replication.51,52 The use of silver has been investigated as a potential
risk to human health and environmental biota depending on the grade of silver used.
Following their entry into systemic circulation, silver particles can migrate and induce
toxicity to many organs.53 On a cellular level, silver is internalized by macrophages and
sorted to the cytoplasm. Intracellularly, released silver ions interfere with mitochondrial
functions and induce apoptotic cell death. Nevertheless, eukaryotic cells show higher
structural and functional redundancy than prokaryotic cells. Thus, much higher silver ion
concentrations (more than 1.6 ppm Ag ions)54 are required to achieve comparable toxic
effects in eukaryotic cells than in prokaryotic ones.
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Our silver release profile study has shown that in the first 24 hours, silver ion levels were at
or below 0.04 ppm. The release of silver ions from both studied starting concentrations
could be detected for up to 7 days (0.05 and 0.06 ppm, respectively). After 14 days, silver
ions were undetectable due to being below the precision limit of the NAA equipment (0.04
ppm) for the 0.5 mg/ml starting concentration of SL. Nevertheless, the biocidal effect of
silver seems to be active at a concentration as low as 0.1 ppb.55 Accordingly, despite our
limitation in quantifying low levels of silver, it is likely that the alginate is able to provide a
sustained release of Ag, as it gradually degrades for several months.51
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Besides the antimicrobial activity of SL-loaded alginate, we also investigated its
osteoconductivity by encapsulating MSCs in the biomaterial. A large amount of mineralized
nodule formation was observed in both the GMSC and hBMMSC groups. After 2 weeks of
encapsulation, both cells were expressing genes related to osteodifferentiation, namely
RUNX2 and OCN. To the best of our knowledge, this is the first time that alginate hydrogel
containing SL has been used for encapsulation of GMSCs and investigated as a treatment
modality for peri-implantitis. A recent study has shown that silver particles do not impair
bone formation by the osteosarcoma MG-63 human cell line.56 Sun et al57 have reported
successful results associating silver nanoparticles, collagen, and bone morphogenetic protein
2 for the regeneration of bone in infected wounds. One especially promising property of our
biomaterial is that, even in the presence of an antimicrobial agent, bone formation was
extensively achieved using GMSCs and hBMMSCs without any additional component, such
as a growth factor.
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Conclusion
A novel noninvasive treatment modality for management of peri-implantitis and periimplant bone loss was introduced based on a micro-encapsulation system that delivers
GMSCs encapsulated in a scaffold of RGD-coupled alginate. This injectable and
biodegradable scaffold can be imbued with antimicrobial properties through the addition of
SL. It was shown that encapsulated GMSCs in SL-containing alginate hydrogel successfully
differentiated into osteogenic tissue. The proposed system possesses the synergistic bone
regenerative properties of GMSCs and the antibacterial properties of SL and can be used as
a novel treatment modality for biofilm-mediated periimplant bone loss.
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SEM image of the alginate hydrogel alone (A) and alginate-MSC construct (B) showing
encapsulated MSCs within porous (C) alginate hydrogel microspheres after 2 weeks of
culturing in regular media. Silver particles (open black arrows) are observed in close contact
with encapsulated MSCs (solid white arrows).
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Figure 2.

Cytotoxicity of a range of concentrations of silver lactate (SL) incorporated into alginate
microspheres after 24 hours (A) and 7 days (B) in contact with GMSCs and hBMMSCs.
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Figure 3.

Silver-releasing profile characteristics from alginate hydrogel.
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Figure 4.

Zone of inhibition produced by the 0 mg/ml (A), 0.5 mg/ml (B) and 2.5 mg/ml (C) SLcontaining alginate microspheres (white arrows).
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Figure 5.

SEM analysis depicting bacterial distribution and morphology along the Ti disc surface
covered with Aa after contact with the 0.5 mg/ml SL alginate microsphere. (A) Interfaces
produced by the contact of the 0.5 mg/ml SL alginate microspheres. Zone of inhibition, ZI;
surface previously covered by the microsphere, *; residues of hydrogel, arrow. (B) Closer
view of residue of the hydrogel. Round shaped Aa (arrows) suggest bacterial death near the
biomaterial (⋆). (C) Aa aggregates in the outer part of the ZI. (D) Aa distribution on the Ti
disc surface outside the ZI.
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Figure 6.

(A) Zone of inhibition quantification in relation tomicrosphere shrinkage for both SL
concentrations after 24 hours and 5 days. (B) Antimicrobial activity of 0.5 mg/ml and 2.5
mg/ml SL concentrations against Aa suspensions after 1, 3, and 5 days. Different letters
show significant differences (*p < 0.05) between groups at the same time points. Asterisks
show significant differences between groups. *p < 0.05, **p < 0.01.
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Figure 7.

Specific gene expression for osteogenic differentiation of encapsulated MSCs in vitro.
Expression level (in fold changes) of OCN and RUNX2 genes for each encapsulated GMSC
(A) and hBMMSC (B) after 2 weeks of culturing in induction media in vitro evaluated by
RT-PCR. Data were normalized by the Ct of the housekeeping gene GAPDH and expressed
relative to the expression level for the same gene at day 1.
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Figure 8.

Qualitative (A) and quantitative (B) measurement of calcium deposition localized to
biomineralized MSC-alginate constructs using Alizarin red dye showing the osteodifferentiation capacity of GMSCs and hBMMSCs encapsulated in alginate with (SL +) and
without SL (SL −). Control groups without mineralization induction were used as the
negative control (−) while encapsulated MSCs without SL (SL −) were used as the positive
group.
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Oligonucleotide primers used in PCR analysis
Gene

Sequence

Runt-related transcription factor 2 (Runx2)

Sense: 5′-CAGTTCCCAAGCATTTCATCC-3′;
  Antisense: 5′-TCAATATGGTCGCCAAA CAG-3′

289

Osteocalcin (OCN)

Sense: 5′-CATGAGAGCCCTCACA-3′; Antisense:
  5′-AGAGCGACACCCTAGAC-3′

292

Glyceraldehyde 3-phosphate dehydrogenase (GADPH)

Sense: 5′-AGCCGCATCTTCTTTTGCGTC-3′:
  Antisense: 5′-TCATATTTGGCAGGTTTTT CT-3′

418
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